Valeant settles the R&O lawsuit that touched off its specialty pharmacy woes

Valeant's ($VRX) relationship with now-dissolved specialty pharmacy Philidor may be the one that has drawn the most scrutiny from short sellers, investors and regulators. But it was litigation from another specialty pharmacy, R&O, that opened up the controversy in the first place. Now, Valeant has settled that R&O lawsuit, it said Wednesday--but that hardly means it's out of the woods. As the Canadian drugmaker recently disclosed, the SEC is investigating, and sources have told The Wall Street Journal that its Philidor connections are the subject of the probe. Release | More

Suggested Articles

Merck is scouting replacements for CEO Ken Frazier with a preference toward an internal candidate, Bloomberg reports.

Bluebird Bio says the launch of Zynteglo, its first gene therapy, will not occur until 2020 while it tightens up its manufacturing processes.

Riival generics makers are squashing long-running lawsuits over their own versions of Sanofi's big-selling blood thinner Lovenox.